Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Paul A. Mahon, Executive Vice President and General Counsel at United Therapeutics Corp (NASDAQ:UTHR), sold 11,000 shares of common stock on July 24, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, conducted under a pre-arranged 10b5-1 trading plan, generated $3.3 million. United Therapeutics, which boasts an impressive 89% gross profit margin and maintains a perfect Piotroski Score of 9 according to InvestingPro, continues to demonstrate strong financial health.
The shares were sold in multiple transactions with prices ranging from $303.3063 to $305.1444. Specifically, 3,769 shares were sold at a weighted average price of $303.3063, totaling $1,143,102. An additional 4,977 shares were sold at an average price of $304.2532, for $1,514,220. The remaining 2,254 shares were sold at an average price of $305.1444, amounting to $687,903.
On the same day, Mahon also exercised stock options to acquire 11,000 shares of United Therapeutics common stock at an exercise price of $135.42, for a total value of $1,489,619.
Following these transactions, Mahon directly owns 36,781 shares of United Therapeutics.
In other recent news, United Therapeutics Corporation has completed enrollment for its phase 3 ADVANCE OUTCOMES study, which evaluates ralinepag for treating pulmonary arterial hypertension (PAH). The study, with 728 participants, will continue to gather clinical worsening events through the end of 2025, with top-line data expected in the first half of 2026. Additionally, Leerink Partners analysts have reaffirmed their Outperform rating for United Therapeutics, maintaining a price target of $418.00. This decision aligns with the company’s upcoming Phase 3 TETON-2 trial readout for idiopathic pulmonary fibrosis (IPF) in the second half of 2025. Meanwhile, UBS has lowered its price target for United Therapeutics to $385.00 from $410.00, citing a favorable risk/reward profile ahead of the IPF readout.
In other developments, Raymond (NSE:RYMD) James analysts have reiterated a Strong Buy rating for Liquidia Technologies (NASDAQ:LQDA) following a favorable court ruling. The court denied United Therapeutics’ request for a temporary restraining order concerning a patent infringement case, removing immediate legal barriers for Liquidia’s Yutrepia. This decision supports Liquidia’s commercialization efforts for treating PAH and pulmonary hypertension associated with interstitial lung disease. These recent developments highlight ongoing advancements and legal proceedings in the pulmonary treatment sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.